Open Nav
Open Nav
Presentations
Check your Inbox
We've sent your certificate
Thank you
for your Feedback!
Presentations
Activity Overview
Faculty & Disclosures
Activity Overview
Faculty & Disclosures
Dr Tal Sella
Sheba Medical Center, Ramat Gan, Israel
Biography
Dr Sella earned his medical degree from Tel Aviv University’s Sackler School of Medicine and trained in medical oncology at Sheba Medical Center, focusing on breast cancer treatment. In 2018, he joined Dana Farber Cancer Institute as a Goldfarb and Rudkin Family international fellow in breast oncology, where he initiated research projects within the Young Women with Breast Cancer Study under the mentorship of Ann Partridge, MD, MPH.
In 2022, Dr Sella returned to Sheba Medical Center, heading the Service for Young Women with Breast Cancer and serving as the medical director of the Oncology Clinical Trials Department. His research focuses on treatment and survivorship of premenopausal and young women with breast cancer, including genetics, fertility, quality of life, adherence, decision-making, and treatment optimization.
Disclosures
Honoraria from Roche, Eli Lilly, Novartis, MSD, Gilead, Astrazeneca and Stemline. Advisory from Novartis. Travel support from Roche, Gilead, Oncotest, Pfizer and Astra-Zeneca.
Dr Alessandra Morelle
Oncoclínicas Porto Alegre, Brazil, CRM - RS 22564
Dr Alessandra Morelle
Oncoclínicas Porto Alegre, Brazil, CRM - RS 22564
Biography
Dr Morelle is an oncologist, with a PhD in Internal Medicine from PUCRS, specializing in the treatment of breast cancer and gynecological tumors. Co-founder of Thummi, a digital support platform for cancer patients, launched in 2018, she integrates technology and innovation to improve health care. She is the creator and instructor of the online course “I have cancer, now what?”, in addition to offering personalized medical follow-up for patients undergoing chemotherapy.
She works in the organization and curatorship of the Future & Innovation Health Forum, an event that promotes discussions about the future of health and technological innovation in the sector. She actively participates in initiatives aimed at personalized medicine, shared decision-making, and new technological approaches to cancer care.
Disclosures
Lectures and educational activities from Astrazeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer, Lilly, Libbs. Advisory board and/or Expert Input Forum from Astrazeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer. Principal investigator of sponsored clinical research studies for Astra Zeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer. Principal investigator of investigator-initiated studies for Astra Zeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer.
Dr Tal Sella
Sheba Medical Center, Ramat Gan, Israel
Presentations
touchMEETING HIGHLIGHTS
This content is intended for healthcare professionals in Brazil, Germany and Spain only.
Please confirm that you are a healthcare professional in one of those countries.
This activity has been funded by Eli Lilly and Company Ltd.
Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.
Close Popup
touchMEETING HIGHLIGHTS
Access to this content is only permitted for healthcare professionals in Brazil, Germany and Spain.
Close Popup
touchMEETING HIGHLIGHTS
This content is intended for healthcare professionals in Brazil, Germany and Spain only.
Please confirm that you are a healthcare professional in one of those countries.
To access this content.
This activity has been funded by Eli Lilly and Company Ltd.
Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.
Close Popup
Could not verify Country/IP Address.
We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.
This activity has been funded by Eli Lilly and Company Ltd.
Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.
No endorsement by Eli Lilly or TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.
The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.
GM-57754; PP-AL-DE-3066; PP-AL-ES-1375
Date of preparation: July 2025
Material destinado exclusivamente a profissionais da saúde prescritores e dispensadores de medicamentos. PP-AL-BR-1650. Julho 2025.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.